Skip to main
DHR
DHR logo

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Danaher Corporation has demonstrated a strong upward trend in performance obligations, increasing from $4.5 billion in 1Q25 to $4.9 billion in 2Q25, indicating robust demand for its products and services. The company is optimistic about a 4.5% growth ramp in the Life Sciences segment for 4Q25, driven by favorable comparisons in Genomics and supportive performance in the China market alongside new product launches. Additionally, the company's service offerings, particularly in Cepheid Respiratory, are expected to generate significant revenue, with projections of $300-350 million in 3Q25 and $450-500 million in 4Q25, showcasing a strong recovery trajectory.

Bears say

Danaher has experienced a decline in its anticipated revenue recognition, with 46% of its second-quarter 2025 obligations expected to be recognized as revenue within the next 12 months, a decrease from 48% in the previous quarter. This decline, coupled with significant risks such as geopolitical disruptions and the uncertain recovery of key high-growth end-markets like China, raises concerns about the company's ability to maintain consistent performance. Additionally, the slightly below-expectations revenue guidance for its Biotechnology and Life Sciences segment further contributes to the negative outlook, as it suggests challenges in meeting growth targets amid lingering macroeconomic headwinds.

Danaher (DHR) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 18 analysts, Danaher (DHR) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $247.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $247.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.